Education
About Us
Working with TipRanks
Follow Us
PABD - ETF AI Analysis
Top Page
iShares Paris-Aligned Climate MSCI World ex USA ETF (PABD)
Rating:65Neutral
Price Target:―
Positive Factors
Climate-Focused Global Exposure
The ETF offers broad exposure to developed markets outside the U.S. while following a Paris-aligned climate approach, appealing to investors who want both diversification and a climate-conscious tilt.
Low Expense Ratio
The fund’s relatively low fee means less of your return is eaten up by costs compared with many specialty or thematic ETFs.
Generally Positive Recent Performance
The ETF has shown steady gains over the past month, three months, and year-to-date, indicating supportive recent market conditions for its strategy.
Negative Factors
Heavy Financial Sector Weight
With a large share of assets in financial stocks, the fund is more exposed to risks tied to banks and financial markets than a more evenly balanced ETF.
Mixed Results Among Top Holdings
While some leading positions like ASML and Mitsubishi UFJ have performed strongly, others such as SAP, Schneider Electric, Royal Bank of Canada, and AstraZeneca have been weaker, which can dampen overall returns.
Limited U.S. Market Participation
Because the ETF excludes most U.S. stocks, investors relying on it alone may miss out on potential gains from the large and influential U.S. equity market.
PABD vs. SPDR S&P 500 ETF (SPY)
AUM312.68M
RegionDeveloped Markets
Expense Ratio0.12%
Beta0.73
IssueriShares
Inception DateJan 17, 2024
Dividend Yield2.7%
Asset ClassEquity
Index TrackedMSCI World ex USA Climate Paris Aligned Benchmark Extended Select Index - Benchmark TR Net
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume22,515
30 Day Avg. Volume10,877
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
76.09Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering414
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PABD Summary
PABD is an ETF that follows the MSCI World ex USA Climate Paris Aligned Index, focusing on companies outside the U.S. that are working to cut carbon emissions and support climate goals. It holds a wide mix of sectors like financials, technology, and health care, and includes well-known names such as ASML and Novartis. Someone might invest in this ETF to get international diversification while supporting more climate-friendly businesses. A key risk is that it can still go up and down with global stock markets and is especially exposed to non-U.S. economies.
How much will it cost me?The iShares Paris-Aligned Climate MSCI World ex USA ETF (PABD) has an expense ratio of 0.12%, meaning you’ll pay $1.20 per year for every $1,000 invested. This is lower than average because it’s passively managed, tracking an index rather than relying on active stock-picking strategies.
What would affect this ETF?Positive drivers for PABD include the growing global focus on sustainability and climate action, which could benefit companies aligned with the Paris Agreement goals. However, economic slowdowns in developed markets outside the U.S. or regulatory changes affecting key sectors like financials and technology could negatively impact the ETF's performance.
PABD Top 10 Holdings
PABD leans heavily on non-U.S. financials and industrials, with a clear climate-transition tilt. ASML is a key engine for returns, riding strong momentum in chipmaking equipment, while ABB and Schneider Electric add extra spark from the industrial side as demand for electrification and automation grows. On the health care front, Novartis, Roche, and AstraZeneca are steadily pulling their weight with solid, if unspectacular, gains. The main drag comes from SAP, which has been losing steam lately, slightly offsetting the broader strength across Europe, Canada, and Australia.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 2.60% | $8.12M | €457.92B | 86.92% | 76 Outperform | |
| Novartis AG | 1.67% | $5.22M | CHF230.74B | 30.93% | 80 Outperform | |
| Roche Holding AG | 1.44% | $4.51M | CHF263.94B | 29.32% | 73 Outperform | |
| AstraZeneca | 1.44% | $4.50M | $300.81B | 24.33% | 80 Outperform | |
| HSBC Holdings | 1.35% | $4.20M | £218.61B | 50.15% | 80 Outperform | |
| Royal Bank Of Canada | 1.31% | $4.10M | $230.52B | 48.64% | 75 Outperform | |
| Schneider Electric | 1.26% | $3.93M | €144.24B | 13.41% | 62 Neutral | |
| ABB Ltd | 1.19% | $3.71M | kr1.46T | 39.17% | 78 Outperform | |
| SAP SE | 1.02% | $3.18M | €188.37B | -31.61% | 66 Neutral | |
| Commonwealth Bank of Australia | 0.97% | $3.03M | AU$288.67B | 19.25% | 64 Neutral |
PABD Technical Analysis
Negative
―
Price Trends
67.36
Negative
65.13
Positive
62.53
Positive
Market Momentum
-0.52
Positive
37.06
Neutral
22.48
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PABD, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 68.21, equal to the 50-day MA of 67.36, and equal to the 200-day MA of 62.53, indicating a neutral trend. The MACD of -0.52 indicates Positive momentum. The RSI at 37.06 is Neutral, neither overbought nor oversold. The STOCH value of 22.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PABD.
PABD Peer Comparison
Comparison Results
Performance Comparison
PABD
iShares Paris-Aligned Climate MSCI World ex USA ETF
65.51
12.17
22.82%
LCTD
BlackRock World ex U.S. Carbon Transition Readiness ETF
―
―
―
FINX
Global X Fintech Etf
―
―
―
SNSR
Global X Internet of Things ETF
―
―
―
IFGL
iShares International Developed Real Estate ETF
―
―
―
FEDM
FlexShares ESG & Climate Developed Markets ex-US Core Index Fund ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents